Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort

Hampshire, Adam; Chatfield, Doris A.; MPhil, Anne Manktelow; Jolly, Amy; Trender, William; Hellyer, Peter J.; Giovane, Martina Del; Newcombe, Virginia; Outtrim, Joanne; Warne, Ben; Bhatti, Junaid; Pointon, Linda; Elmer, Anne; Sithole, Nyaradzai; Bradley, John R.; Kingston, Nathalie; Sawcer, Stephen; Bullmore, Edward T.; Rowe, James B.; Menon, David K.

doi:10.1016/j.eclinm.2022.101417

Cited by 82 publications

(73 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Memory impairment, brain fog, poor attention, or difficulty thinking have been reported by other authors in 22%–88% of patients with lasting symptoms [ 5 , 25 , 27 , 28 ], but these prevalences did not take into consideration the contribution of mood disorders or fatigue, highly associated with cognitive abnormalities and also features of PCC [ 6 , 7 ]. Objectively measured cognitive deficits were reported among 46 patients 6 months after severe COVID-19, independent of mental health and fatigue [ 29 ]. We similarly observed that the prevalence of cognitive symptoms was 2–3 times higher among patients with PCCs compared to non–COVID-19 HCWs, whose baseline prevalence was as high as 14%.…”

Section: Discussionmentioning

confidence: 99%

Physical, Psychological, and Cognitive Profile of Post-COVID Conditions in Healthcare Workers, Quebec, Canada

Carazo

Skowronski

Laforce

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The prevalence of post-COVID conditions (PCC) and associated physical, psychological and cognitive symptoms was assessed among Quebec healthcare workers (HCWs) with COVID-19. Methods This case-control study compared 6061 symptomatic HCWs with PCR-confirmed COVID-19 between July 2020 and May 2021 with a random sample of 4390 symptomatic HCWs who were test-negative controls. The prevalence of physical symptoms lasting ≥4 weeks (PCC4w) or ≥12 weeks (PCC12w) was estimated among hospitalized and non-hospitalized cases. In multivariate models, sociodemographic and clinical characteristics, as well as vaccine history, were evaluated as potential risk factors. Prevalence ratios compared four aspects of self-reported cognitive dysfunction among PCC cases to controls, adjusting for psychological distress and fatigue. Results PCC4w and PCC12w prevalences of 46% (2,746/5,943) and 40% (653/1,746), respectively, were observed among non-hospitalized cases and 76% (90/118) and 68% (27/37), respectively, among hospitalized cases. Hospitalization, female sex and age were associated with higher PCC risk. A substantial proportion of non-hospitalized PCC4w cases often or very often reported cognitive dysfunction, including concentration (33%) or organizing (23%) difficulties, forgetfulness (20%) and loss of necessary items (10%). All four aspects of cognitive dysfunction were associated with PCC4w symptoms, psychological distress and fatigue. Conclusion PCC may be a frequent sequela of ambulatory COVID-19 in working-age adults, with important effects on cognition. With so many HCWs infected, the implications for quality healthcare delivery could be profound if cognitive dysfunction and other severe PCC symptoms persist in a professionally-disabling way. Further evaluation of PCC prevalence and prognosis is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Physical, Psychological, and Cognitive Profile of Post-COVID Conditions in Healthcare Workers, Quebec, Canada

Carazo

Skowronski

Laforce

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…Tracking seroprevalence due to vaccination is an important issue, since vaccination contributes to the reduction of hospitalization among Covid-19 patients. A preliminary evidence has highlighted a possible association between severe COVID-19 and persistent cognitive deficits [17]. Further research is required to confirm this association, determine whether cognitive deficits relate to clinical features from the acute phase or to mental health status at the point of assessment, and quantify rate of recovery.…”

Section: Discussionmentioning

confidence: 99%

Seroprevalence of SARS-CoV-2 Antibodies among vaccinated and non-vaccinated adults in the West Bank: Results of a repeated cross-sectional study

Awartani

Qutob

Asia

et al. 2022

Preprint

View full text Add to dashboard Cite

BackgroundSeroprevalence studies provide an accurate measure of SARS-CoV-2 spread at a population level and the number of undiagnosed individuals. Repeated cross-sectional sero-studies are encouraged to monitor the spread of the virus. The aim of this study is to assess the seroprevalence rate among a random sample of Palestinians residing in the West Bank region of Palestine.MethodsThis second round cross-sectional study involved 1451 participants. serologic testing of a random sample of vaccinated and non-vaccinated adults, 18 years and older residing in 11 governorates of the West Bank region of Palestine. Antibodies/Blood samples were taken using Elecsys Anti-SARS-CoV-2 assay by using the Cobas Analyzer cobas e 411 (Roche) for detection of antibody seropositivity against COVID-19.Serological tests for 910 adequate serum samples were done using immunoassays for detection of antibodies against SARS-CoV-2. Sociodemographic information and medical history data was collected.ResultsStudy findings indicate that as of October 2021, a seroprevalence rate of 75.9% (30% due to infection with Covid-19 virus and 45.9% due to vaccination), 95% CI (73.1-78.7). The results indicate that the prevalence of antibodies among those who unvaccinated and undiagnosed cases was 45.2% with 95% CI (39.9-50.5%).The average age of participants was 37.6 years old. 49.2% were female and 50.8% were male. In relation to COVID-19, the following was found:ConclusionOur findings reveal a drastic rise in seroprevalence of SARS-CoV-2 antibodies both due to infection and due to vaccination. This information is useful for assessing the degree of herd immunity, and provides better understanding of the pandemic. Population-based seroprevalence studies should be conducted periodically to monitor the SARS-CoV-2 seroprevalence in Palestine and inform policymakers about the efficacy of the surveillance system and the public compliance with vaccination policies.

show abstract

“…Another study showed that 8% of COVID-19 survivors had persistent cognitive dysfunction [143]. Being hospitalized for severe COVID may age the brain by 20 years, but even patients with asymptomatic Covid-19 may have prolonged cognitive dysfunction [153]. One study showed lower Montreal Cognitive Assessment (MoCA) scores in patients with asymptomatic COVID-19 than healthy controls [154].…”

Section: Epidemiology and Presentationmentioning

confidence: 99%

Therapeutic Approaches to the Neurologic Manifestations of COVID-19

2022

View full text Add to dashboard Cite

As of May 2022, there have been more than 527 million infections with severe acute respiratory disease coronavirus type 2 (SARS-CoV-2) and over 6.2 million deaths from Coronavirus Disease 2019 (COVID-19) worldwide. COVID-19 is a multisystem illness with important neurologic consequences that impact long-term morbidity and mortality. In the acutely ill, the neurologic manifestations of COVID-19 can include distressing but relatively benign symptoms such as headache, myalgias, and anosmia; however, entities such as encephalopathy, stroke, seizures, encephalitis, and Guillain-Barre Syndrome can cause neurologic injury and resulting disability that persists long after the acute pulmonary illness. Furthermore, as many as one-third of patients may experience persistent neurologic symptoms as part of a Post-Acute Sequelae of SARS-CoV-2 infection (Neuro-PASC) syndrome. This Neuro-PASC syndrome can affect patients who required hospitalization for COVID-19 or patients who did not require hospitalization and who may have had minor or no pulmonary symptoms. Given the large number of individuals affected and the ability of neurologic complications to impair quality of life and productivity, the neurologic manifestations of COVID-19 are likely to have major and long-lasting personal, public health, and economic consequences. While knowledge of disease mechanisms and therapies acquired prior to the pandemic can inform us on how to manage patients with the neurologic manifestations of COVID-19, there is a critical need for improved understanding of specific COVID-19 disease mechanisms and development of therapies that target the neurologic morbidities of COVID-19. This current perspective reviews evidence for proposed disease mechanisms as they inform the neurologic management of COVID-19 in adult patients while also identifying areas in need of further research.

show abstract

Multivariate profile and acute-phase correlates of cognitive deficits in a COVID-19 hospitalised cohort

Cited by 82 publications

References 33 publications

Physical, Psychological, and Cognitive Profile of Post-COVID Conditions in Healthcare Workers, Quebec, Canada

Physical, Psychological, and Cognitive Profile of Post-COVID Conditions in Healthcare Workers, Quebec, Canada

Seroprevalence of SARS-CoV-2 Antibodies among vaccinated and non-vaccinated adults in the West Bank: Results of a repeated cross-sectional study

Therapeutic Approaches to the Neurologic Manifestations of COVID-19

Contact Info

Product

Resources

About